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ABSTRACT
Environmental factors such as high saturated fat content in a diet affect pro- and antioxidative balances in metabolic tissues. High-dietary fat intake 
promotes the development of obesity and metabolic disorders in humans and rodents as a result of disproportion between energy intake and energy 
expenditure. The dreaded events of high-fat diet (HFD) are obesity, hypertension, cardiovascular and cerebrovascular anarchy, Type II diabetes, 
infertility, and even cancer. HFD - induced systemic oxidative stress insults an imbalance between oxidants derivatives production and antioxidants 
defenses. Reactive oxygen species are mostly reasoned to be detrimental for health. Many evidences regarding HFD - elicited oxidative stress gathered 
over the past few years based on established correlations of biomarkers or end-products of free-radical-mediated oxidative stress. The hypothesis 
that oxidative stress plays a prodigious role in the development of metabolic disorders, especially insulin resistance, hyperlipidemia, cardiovascular 
disease or hepatic steatosis, and steatohepatitis. In this review, we elucidated the mechanistic links between HFD - induced oxidative stress and its 
impact on metabolic complications development.
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INTRODUCTION
High-fat diet (HFD) is a most important risk factor for a plethora 
of severe ailments, including obesity, dyslipidemia, cardiovascular 
disease, Type II diabetes, non-alcoholic fatty liver, non-alcoholic 
steatohepatitis (NASH), and cancer [1-3]. The increased occurrence of 
obesity and obesity-associated impediment continues to be a global 
health issue. Multifactorial reasons, such as high-fat, caloric-dense 
diets, sedentary lifestyles, increased urbanization, and psychosocial 
hassles, are the most frequent contributing factors for the inception of 
metabolic syndrome (MetS) [4]. The prevalence of MetS raises with the 
use of high saturated fat as an imminent component of many food stuffs 
and increases morbidity in obese youngsters [5]. The mechanisms for 
increased oxidative stress in the MetS are not completely understood 
but include increased fatty acid oxidation, mitochondrial dysfunction, 
and augmented NADPH oxidase activity. Most studies so far focus on 
relating abnormal gene expression in the liver and adipose tissues to 
HFD, accompanied by augmented expression of NADPH oxidase and 
decreased expression of antioxidative enzymes [6,7]. HFD provoked 
dyslipidemia which is linked to oxidative stress, an accumulation of 
several transition metals as well as increased free radicals [8]. Fat 
accumulation associated with systemic oxidative stress in humans and 
mice through increased production of reactive oxygen species (ROS) 
accompanied by enhanced expression of NADPH oxidase and reduced 
expression of antioxidative enzymes [7,9]. HFD increases NADPH 
oxidase activation, oxidative stress, and lipid peroxidation caused 
deregulated production of redox-sensitive transcription factor-nuclear 
factor kappa beta (NF-κB), adipocytokines (fat-derived hormones), 
including adiponectin, plasminogen activator inhibitor-1, IL-6, and 
monocyte chemotactic protein-1 (MCP-1), and other inflammatory 
cytokines form different metabolic tissues [9,10].
In this review, we will represent mechanistic relations linking 
to oxidative stress generated by high saturated fat in the context 
of deregulation of different body parameters associated with fat 
metabolism and its impact on metabolic complications development. 
We will particularly focus on how HFD associated with oxidative stress, 
obesity, deregulation of adenosine monophosphate-activated protein 
kinase (AMPK) activity, pathophysiological and biochemical changes 
in the gut, liver, heart, and blood vessels which ultimately lead to the 
progression of MetS.
HFD - INDUCED OXIDATIVE STRESS, A KEY FACTOR FOR 
PATHOPHYSIOLOGICAL CHANGES IN MetS
HFD increases the amount of chylomicrons in the intestine. The 
later upon entry into the circulation leads to generate free fatty acid 
(FFA) that is taken up by the liver. These hepatic FFAs either enter 
mitochondria for β oxidation or esterified to form triglycerides (TG). 
These TGs are either accumulated in the hepatocytes as tiny droplets or 
produces very low-density lipoprotein (VLDL) which in turn converts 
into LDL [11]. Too much LDL burden in the blood due to its excessive 
generation as well as due to lack of LDL-receptor in hepatocytes forms 
oxidized-LDL (Ox-LDL) those are engulfed by macrophages to become 
foam cells. They accumulate in the arterial endothelium and forms 
plaque. It ultimately leads to circulatory and cardiovascular disorders 
such as atherosclerosis, hypertension, thromboembolism, heart block, 
etc. [12-14]. FFA generated from fat digestion and metabolism either 
enter mitochondria for oxidation or are esterified into TG [11]. The 
mitochondrial β-oxidation of FFAs is associated with the conversion of 
oxidized cofactors (NAD+ and FAD) into reduced cofactors NADH and 
FADH2, which in turn gets reoxidized and back into NAD+ and FAD by a 
mitochondrial respiratory chain. During their reoxidation, NADH and 
FADH2 transfer their electrons to the first complexes of the respiratory 
chain. Most of these electrons migrate up to cytochrome-c oxidase, 
where they safely combine with oxygen and protons to form water; 
but a fraction of these electrons directly reacts with oxygen to form the 
superoxide anion radical and other ROS. Hence, excess intake of fat-
rich diets increases mitochondrial β oxidation of FFAs. It leads to an 
excess electron flow using cytochrome-c oxidase and thereby enhances 
the production of ROS. Moreover, mitochondria are the most important 
cellular source of ROS, which oxidize the unsaturated lipids of fat deposits 
to cause lipid peroxidation. These intermediates react with oxygen to 
form more and more superoxide anion and other ROS [15,16]. Lipid 
peroxidation and ROS can consume antioxidant enzymes and vitamins 
as well [15]. Depletion of these protective substances may hamper 
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ROS inactivation and increase lipid peroxidation and ROS-mediated 
damage [7]. This HFD - induced ROS directed pro-inflammatory 
state may activate one of the major transcription factor linked with 
inflammation, NF-κB. Moreover, either this HFD triggers ROS or NF-κB 
induces the expression of NF-κB-dependent pro-inflammatory agents 
namely, inducible nitric oxide synthase (iNOS), tumor necrosis factor 
(TNF-α) interferon γ (IFN-γ) [17]. This cause overproduction of nitric 
oxide (NO) by activated iNOS; in turn increased generation of reactive 
nitrogen species (RNS) is imminent due to the interaction between 
superoxides and NO [2,18]. All these interlinked events may explain 
the reasons for the development of multiple risk factors and chronic 
disorders on high-fat consumption, systemic oxidative stress, and MetS.
HFD – INDUCED ROS PRODUCTION IN ADIPOSE TISSUE AND 
PROGRESSION OF MetS
Studies showed that elevated ROS is produced from hypertrophoid 
adipocytes from HFD. Fat mass expansion occurs via two processes 
concomitantly occurring during white adipose tissue expansion 
including hypertrophy (increasing size of fat cells) and hyperplasia 
(more numbers of fat cells linked to differentiation of adipocyte 
precursors) [19,20]. Many studies have established a close association 
between ROS and adipogenesis. Fat accumulation parallels ROS 
production, as established by increased ROS production during 
adipocyte 3T3-L1 alteration [21]. Leptin, a white adipose tissue-
derived hormone, has been shown to increase the generation of ROS 
in endothelial cells [22,23]. NF-κB is also activated by leptin in an 
oxidant-dependent manner. This effect is linked with an enhanced 
expression of MCP1, which promotes atherosclerosis by supporting 
the relocation of inflammatory cells [19,22]. Stimulation of ROS by 
leptin occurs via protein kinase C-dependent activation of NAD(P)
H oxidase in vascular smooth muscle cells [24]. In addition, leptin, 
at concentrations related to those found in the plasma of diabetic 
patients, stimulates the release of active macrophage lipoprotein 
lipase through an oxidative stress-dependent pathway signifying 
a proatherogenic effect of leptin on macrophages in diabetes [25]. 
Exposition of adipocytes to high ROS levels restrain adiponectin 
expression and secretion [9,26], an adipokine which exhibits insulin-
sensitizing, antiatherogenic, and anti-inflammatory properties [27]. 
Therefore, human serum adiponectin levels have been inversely allied 
with systemic oxidative stress [9,28].
HFD – EVOKED PATHOPHYSIOLOGICAL CHANGES OF THE GUT IN 
MetS
Low-grade inflammation with high-fat and obese patients corresponds 
with augmented plasma levels of C-reactive protein, TNF-α, IL-6, MCP-1, 
IL-8, osteopontin, and leptin [20]. Spagnuolo et al. suggested a significant 
positive correlation between body mass index and C-reactive protein 
which may lead to obesity-associated complications [29]. Obesity 
and diabetes modify the glucose-stimulated gut to hypothalamic 
NO signaling pathway. The disturbed enteric glucose detection is 
linked with a significant increase in inflammatory, oxidative/NO, and 
endoplasmic reticulum (ER) stress gene expression [30,31]. Signaling 
mechanisms reported to promote inflammation have been established 
to be started and mediated by luminal lipid and gut microbiota [32,33]. 
These observations suggested the significance of preserving gut 
function, and a greater understanding of the pathological condition 
of the gut may be helpful in finding new approach to treat and to 
avert obesity and associated disorders [30]. Lee assessed that main 
factor that contributes to the development of obesity is high-fat 
consumption. Lipid absorption begins from the gastrointestinal tract/
gut on the basis of feedback mechanisms to regulate glucose and lipid 
metabolisms. Lipid-sensing pathways are impaired in HFD - induced 
insulin resistance, ensuing in hyperglycemia. In addition, lipid in the 
duodenum activates mucosal mast cells, leading to the disruption of the 
intestinal tight junction. Lipopolysaccharide which is co-transited with 
postprandial fat consumed with diet promotes the release of cytokines 
and may be linked with the development of metabolic syndrome. HFD 
also modifies microbiota composition and increases fat storage. Though 
the gut is protected by the immune system and contains a high level 
of antioxidants, obesity developed most likely when this protective 
mechanism is compromised by the presence of too much fat [6].
HFD - INDUCED OXIDATIVE STRESS AND CARDIOVASCULAR 
DYSFUNCTION IN MetS
The MetS increase the risk for cardiovascular disease and Type II 
diabetes. Each factor of the MetS causes cardiac dysfunction, and their 
combination carries additional risk. The etiology of cardiovascular 
diseases in patients with MetS may involve coronary atherosclerosis, left 
ventricular hypertrophy, arterial hypertension, diastolic dysfunction, 
endothelial dysfunction, coronary micro-vascular disease, and 
autonomic deregulation. One common characteristic of cardiovascular 
disease in the MetS is increased oxidative stress in the heart [34,35]. In 
reality, patients with the MetS have elevated systemic oxidative damage 
as a result of ROS production and decreased antioxidant defense [36,37]. 
HFD evoked magnified ROS production and the decrease in antioxidant 
capacity leads to a variety of anomalies such as endothelial dysfunction 
that is characterized by a reduction in the bioavailability of vasodilators, 
mostly NO, and an increase in endothelium-derived contractile factors, 
promoting atherosclerotic disease [38]. The mechanisms for increased 
cardiac oxidative stress in the MetS are not completely unstated but 
include augmented fatty acid oxidation, mitochondrial dysfunction, and 
an increased NADPH oxidase activity [38]. Ilkun and Boudina evaluated 
the mechanisms underlying cardiac pathology in the MetS are complex 
and might include lipid accumulation, altered calcium homeostasis, 
increased fibrosis and stiffness, abnormal autophagy, mitochondrial 
dysfunction, and increased oxidative stress. Mitochondrial and 
extra-mitochondrial sources of reactive oxygen species and reduced 
antioxidant defense mechanisms characterize the myocardium of 
animals and humans with MetS [38].
HFD - INDUCED OXIDATIVE STRESS IN THE PROGRESSION OF 
NON-ALCOHOLIC FATTY LIVER (NAFL) AND NASH IN MetS
NAFL is defined as the presence of hepatic steatosis with no evidence 
of hepatocellular injury in the form of ballooning degeneration of the 
hepatocytes. NASH is defined as the presence of hepatic steatosis and 
inflammation with hepatocyte injury (ballooning) with or without 
fibrosis. [39]. High-fat induced weight gain promotes hepatic oxidative 
stress, triggers the redox-sensitive transcription factor such as NF-κB, 
some inflammatory processes, prevalence of hepatic steatosis, and 
other liver lesions called steatohepatitis [40-46]. Another redox-
sensitive transcription factor, i.e., nuclear factor E2-related factor 2 
(Nrf2) up-regulates a battery of antioxidative genes and cytoprotective 
enzymes that constitute the cellular response to oxidative stress; 
however, the chronic stress factors are liable for the diminished 
function of Nrf2 [47]. Indeed, chronic fat ingestion (inflammation) 
plays a role in the development of insulin resistance and other obesity-
related features commonly recognized as MetS in both developed 
and developing countries [48-50]. Hepatic TG accumulation is an 
etiological factor for NAFLD or is associated with steatohepatitis [51]. 
NASH develops via the “two-hit” model [52]. Insulin resistance shows 
to be the “first-hit” which provokes fat accumulation in hepatocytes 
along with diminution in the insulin signaling pathway activity [53]. 
“Second-hit” includes HFD, obesity, diabetes, hyperlipidemia, oxidative 
stress along with hepatocyte apoptosis which is supposed to play a 
fundamental role in the pathogenesis of NAFLD [54]. HFD inhibits the 
metabolic phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) 
signaling pathway which may lead to activation of the mitochondria-
dependent apoptosis [55]. Apoptosis in HFD - induced NASH activates 
c-Jun NH2-terminal kinase (JNK) and elevates proapoptotic Bax. In 
addition, oxidative stress and its associated JNK activation, as well as 
an imbalance of pro and anti-apoptotic proteins in the Bcl-2 family, 
contribute to high hepatocyte apoptosis which plays an important 
role in the pathogenesis of NASH [56]. NAFLD encompasses a large 
spectrum of conditions ranging from fatty liver to NASH, which 
can develop cirrhosis and cancer [39]. Study reports revealed the 
association between the levels of lipid oxidation products and disease 
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state. However, often neither oxidative stress nor ROS has been 
characterized, despite oxidative stress is mediated by multiple active 
species by different mechanisms and the same lipid oxidation products 
are produced by different active species [40,57].
HFD - INDUCED OXIDATIVE STRESS AND AMPK ACTIVITY IN MetS
The AMPK system is a key player in regulating energy homeostasis 
at both the cellular and whole-body levels, placing it at center stage 
in studies of obesity, diabetes, and the MetS [58]. AMPK comprised 
of a heterotrimeric complex including a catalytic α subunit and 
regulatory β and γ units. There are two isoforms of α (α1and α2) 
and β (β1 and β2) and three γ subunits (γ1-3) which are differently 
expressed in mammalian tissue [58]. AMPK activation can induce 
ATP (adenosine triphosphate) generation through pathways such as 
glycolysis and β-oxidation. On the contrary, ATP-consuming pathways, 
including fatty acid and cholesterol syntheses, and gluconeogenesis, 
are suppressed by AMPK activation [59]. HFD substantially decreased 
the activities of both isoforms of AMPK in white adipose tissue, heart, 
and liver. These decreases in AMPK activity happens in the absence of 
reduced AMPK transcription, systemic inflammation, hyperglycemia, or 
high levels of FFA. The HFD - induced decrease in AMPK activity was 
associated with systemic insulin resistance and hyperleptinemia [60]. 
Due to the vital role of AMPK in modulating these aspects of energy 
balance, it is not surprising that modifications in AMPK have been 
concerned in the commencement of obesity and MetS [61-63]. There 
are several studies indicating that the activation of AMPK represses 
the oxidative stress triggered by different insults such as fatty acids 
and hyperglycemia [64-67]. Xie et al. observed that AMPK signaling 
induced the expression of mitochondrial uncoupling protein-2 (UCP-2) 
and accordingly reduced the production of superoxide radicals in 
hyperglycemic endothelial cells. It is known that UCP-2 is able to inhibit 
the mitochondrial ROS production [66]. Wang et al. demonstrated using 
different techniques that AMPKα2 is the physiological suppressor of 
the ROS produced through NAD(P)H oxidase. These results support 
the mechanism whereby AMPK inhibits the NF-κB signaling and thus 
down-regulates the expression of several NAD(P)H oxidase subunits 
and thus lessens oxidative stress [64]. Li et al. revealed that AMPK 
signaling via the AMPK - Forkhead box O (FoXO3) pathway induced 
the expression of thioredoxin (Trx), a disulfide reductase which defend 
cellular proteins against cysteine oxidation [65]. The ER is a sensitive 
stress sensor in the maintenance of cellular protein quality and 
nutrient balance [68,69]. Oxidative stress impairs homeostasis in ER 
and leads to misfolding of proteins in ER and calcium release into the 
cytoplasm. ER stress triggers set of transducer proteins that stimulate 
the unfolded protein response (UPR) [69]. Studies have explored that 
the UPR involves the activation of NF-κB system which can trigger a 
low-grade inflammatory response [70-72]. Study reports showed that 
AMPK activity can decrease the ER stress, e.g., in Oxidized-LDL-exposed 
aortic endothelial cells and in hypoxic cardiomyocytes [73,74]. Dong 
et al. demonstrated that the deletion of AMPKα2 augmented ER stress 
in endothelial cells and responsible for aortic lesions in the knockout 
mice. They also noted that several antioxidants were able to suppress 
the manifestation of ER stress. This indicates that ER stress is provoked 
by oxidative stress induced by the deletion of AMPKα2 [73]. Salminen 
et al. reviewed that AMPK signaling can inhibit the inflammatory 
responses which are induced by the NF-κB system. The NF-κB subunits 
are not direct phosphorylation targets of AMPK, but the suppression of 
NF-κB signaling is mediated by several downstream targets of AMPK, 
e.g., SIRT1, PGC-1a, p53, and FoxO factors. AMPK signaling appears 
to improve energy metabolism while it can repress inflammatory 
responses related to chronic stress, e.g., in nutritional overload [75].
SUMMARY AND CONCLUSION
MetS is defined by a constellation of integrated physiological, 
biochemical, clinical, and metabolic factors that directly increases the 
risk of dyslipidemia, cardiovascular disease, Type II diabetes, and all-
cause mortality. Oxidative stress in metabolic tissues has emerged as 
a widespread feature of MetS and its co-morbidities. The consumption 
Fig. 1: Mechanism involved in high-fat diet-induced increased 
level of free fatty acid (FFA) production. These FFAs undergoes 
mitochondrial β-oxidation process and are responsible to 
generate oxidative stress through production of reactive oxygen 
species and reactive nitrogen species
Fig. 2: Potential mechanism for high-fat diet - induced 
alterations in the adipose tissue cells. The accumulation of 
lipids in adipose tissue and the expansion of the fat mass lead 
to the initiation of an inflammatory process and progression of 
metabolic syndrome
Fig. 3: A mechanism that contributes to high-fat diet (HFD) - 
induced gut pathophysiological changes. HFD impairs gut 
lipid-sensing mechanisms and affects glucose homeostasis 
through increased hepatic glucose production. Interaction 
between microbiota and HF leads to the excessive release of 
adipocytokines, consequently obesity, and metabolic syndrome 
development
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of high energy diets (carbohydrate, protein, and fat) has turned out to 
be a practice in modern societies regardless of the lessening in daily 
energetic requirements. Oxidative stress has come into view in recent 
years as a characteristic of the metabolic disorders, fundamentally 
Fig. 4: A multipronged mechanism that contributes to high-fat diet (HFD) - induced oxidative stress and NAFL/NASH in metabolic 
syndrome. HFD is responsible for hepatic alterations and inflammation through the production of inflammatory cytokines and lipid 
peroxidation. Involvement of PI3K/Akt, Jun NH2-terminal kinase, Bax, Bcl2 pathways is responsible for hepatocyte apoptosis which is one 
of the important features for the development of non-alcoholic steatohepatitis. ↑↓ arrow indicates increased and or decreased outcome, 
respectively
Fig. 5: Systemic metabolic alterations associated with high-fat diet (HFD) contribute to the increase in oxidative stress. Altogether, 
metabolic parameters such as obesity, dyslipidemia, AMPK deregulation, gut pathophysiological changes, insulin resistance, Type II 
diabetes, cardiovascular anomalies, and non-alcoholic fatty liver/non-alcoholic steatohepatitis, are closely related with HFD - induced 
reactive oxygen species production and this dysregulation played crucial role for progression of metabolic complications
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associated with chronic low-grade inflammation. Close relations exist 
between MetS and oxidative stress due to an imbalance between pro-
oxidant and antioxidant species in favor of oxidized entities. In reality, 
patients with MetS show signs of damage due to oxidative stress. In 
general, systemic oxidative stress-associated HFD and obesity directly 
impacts insulin sensitivity of metabolic organs, promotes inflammation. 
Overall, oxidative stress shows as an essential contributor of metabolic 
ailment associated HFD like obesity, derangement of lipid profiles, 
Type II diabetes, cardiovascular diseases, NAFL/NASH, and AMPK 
dysregulation. MetS is a condition that is an outbreak and has inflated 
in current decades. The study of MetS has undergone substantial 
development parallel to the increase of this metabolic disorder. 
Proficient and skilled research in various fields allowing changes in 
views on HFD, oxidative stress, MetS, and the pathophysiology of the 
disease that prevail at present. The perturbation of old paradigms and 
the new knowledge platform provide a solid base for understanding the 
disease and for developing strategies for prevention and management. 
Overall, further studies are wanted to clearly comprehend and manage 
the degree of ROS generation, types, and distribution in metabolic 
tissues as well as at the organismal level. This can show the way to 
develop new strategies to combat the disorders associated with HFD 
and MetS.
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